Neil H. Bander, MD

Professor Emeritus of Urology

Contact & profiles

Appointments

Past Appointments

Bernard and Josephine Chaus Professor of Urological Oncology
Urology · 1999–2023
Professor of Urology
Urology · 1999–2023
Associate Professor of Urology
Urology · 1993–1998

Show all 7

Bernard And Josephine Chaus Associate Professorship of Urological Oncology in Urology
Urology · 1993–1998
The Bernard and Josephine Chaus Associate Professorship Urological Oncology
Surgery · 1991–1993
Associate Professor of Surgery (Urology)
Surgery · 1989–1993
Assistant Professor of Surgery (Urology) in Surgery
Surgery · 1983–1989

Centers

Education

Highlights

1
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
STScott T. Tagawa SVShankar Vallabhajosula SHSandra Huicochea Castellanos JTJones T. Nauseef+4 more →NHNeil H. Bander
PMID: 37922438PMCID: PMC10906595DOISenior author67 citations

179

2 grants

Co-I
Optimization of Prostate-Specific Membrane Antigen-Targeted Radiation
Prostate Cancer Foundation · 2017–2027
17CHAL11
Co-I
Heating cold prostate tumors with PSMA-targeted alpha therapy and pembrolizumab
U.S. Department of Defense · 2020–2026
W81XWH-20-1-0706

Completed grants (5)

KP
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
National Cancer Institute · 2017–2023
P50CA211024-05
PI
Tumor-Targeted Alloantigen Biosynthesis: Converting Tumor to Incompatible Allograft
Daedalus Fund for Innovation (Weill Cornell) · 2020–2022BioPharma Alliance
BP 202763-02
PI
Molecular and clinical correlates with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy
U.S. Department of Defense · 2018–2022
W81XWH-18-1-0528
KP
A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591 in Patients with High-Risk Castrate Biochemically Relapsed...
U.S. Department of Defense · 2009–2019
W81XWH-09-1-0596
MPI
Ph. I humanized mAb huJ591-DOTA-177Lu/ relapsed prostate cancer
NCRR · 1997–2005 · via NIH RePORTER
M01RR000047-44

New Radiopharmaceutical Shows Antitumor Activity in Patients with Advanced Prostate Cancer
November 3, 2023
Researchers at Weill Cornell Medicine have led a phase 1 trial of a new drug that delivers potent radiation therapy directly and specifically to cancer cells in patients with advanced prostate cancer. The clinical trial showed that the “radiopharmaceutical” was well tolerated and demonstrated promising antitumor activity.
Researchers Awarded $1 Million to Study Optimal Use of Radioactive Drugs for Prostate Cancer Therapy
January 4, 2019
Researchers at Weill Cornell Medicine, in collaboration with investigators at Dana-Farber Cancer Institute, have been awarded a three-year, $1 million grant from the U.S. Department of Defense (DoD) for prostate cancer clinical trials.